Botensilimab (also known as AGEN1181) is a multipurpose, second-generation “Fc-engineered” anti-CTLA-4 antibody with enhanced tumor fighting abilities, designed to generate responses in a larger number of patients and improve immunogenicity.
The clinical performance of botensilimab has been consistent with its design. More than 100 patients have been treated to date in a Phase 1 study; Botensilimab is the first anti-CTLA-4 antibody to demonstrate clinical activity in 9 cold, treatment-resistant tumors as monotherapy and in combination with PD-1 (balstilimab). Below is a summary of the data presented at the SITC 2021 meeting:
- Four cases of confirmed objective response – first reported CTLA-4 monotherapy response in endometrial, pancreatic and PD1 r/r cervical
- Multiple responses in patients expressing the low affinity FcyRIIIA receptor (F/F), who are unlikely to respond to first generation CTLA-4
Combination activity (botensilimab + balstilimab)
- CRC: 14 of 20 pts benefited from combo; 4 PRs, 10 SDs
- Ovarian: 5 of 9 patients benefited from combo; 3 PRs, 2 SDs
- Endometrial: 3 of 3 pts benefited from monotherapy and combo; 1 CR, 2 PRs
- Durability: Responses in this Phase 1 trial have been durable, with half lasting at least 24 weeks and the majority ongoing
Based on this data, multi-arm, randomized phase 2/3 trials investigating botensilimab as monotherapy and in combination with balstilimab in MSS-CRC and gynecological cancers (ovarian and MSS-endometrial cancer) are being initiated. The design of these trials may support a potential filing for full and/or accelerated approval based on the magnitude of benefit demonstrated in the studies.
Discovery of Botensilimab and its Mechanism of Action
Agenus scientists discovered a new mechanism of action in which a specialized domain of the antibody engages with receptors on other immune cells to significantly bolster antitumor immunity. This discovery was published in Cancer Cell.
To develop botensilimab, Agenus leveraged the above discovery to modify a part of the antibody known as the Fc region, which interacts with other immune cells to enhance antitumor immunity. In pre-clinical studies, this “Fc-engineered” antibody significantly improved the cross-talk between antigen presenting cells (APCs) and T cells. In cancer immunotherapy, such an interaction is necessary to mount a potent immune response against cancer.
Latest Clinical Trials
Latest Publications and Abstracts
November 10-14, 2021
AGEN1181, an Fc-enhanced anti-CTLA-4 antibody, alone and in combination with balstilimab (anti-PD-1) in patients with advanced solid tumors: Initial phase I results. El-Khoueiry, et al.
April 9-14, 2021
Fc-enhanced anti-CTLA-4 Antibody, AGEN1181: New Mechanistic Insights for Potent Antitumor Immunity and Combination Potential in Treatment-resistant Solid Tumors. Tanne, et al.
April 9-14, 2021
Characterization of The Pharmacodynamic Activity of AGEN1181, an Fc-enhanced CTLA-4 Antibody, Alone and in Combination With the PD-1 Antibody Balstilimab. Shapiro, et al.
November 9-14, 2020
AGEN1181, an Fc engineered anti-CTLA-4 antibody, demonstrates clinical activity, alone or in combination with balstilimab (anti-PD-1), and broadens the therapeutic potential of CTLA-4 therapy. O'Day, et al.
June 22-24, 2020
Expanding the Therapeutic Potential of anti-PD-1 and anti-CTLA-4 Therapy with Innovative Fc Engineering and Rationale Combinations for the Treatment of Solid Tumors. Tanne, et al.
May 29-31, 2020
AGEN1181, a Clinical Stage Fc-Engineered anti-CTLA-4 Antibody with Improved Therapeutic Potential for the Treatment of Patients with Advanced Malignancies. O'Day, et al.
November 18, 2019
New mechanistic insights from TME reconditioning by an Fc engineered anti-CTLA-4 antibody. Vincent, et al.